Trends in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019−2023

Carbapenem-resistant Enterobacterales (CRE) have several ways of evading antibiotics, including efflux pumps, porin mutations, penicillin-binding protein (PBP) mutations, and carbapenemases. Traditionally, most carbapenemases among U.S. Enterobacterales were serine-based and therefore managed by most of the novel beta-lactamase inhibitors (BLIs), such as avibactam, vaborbactam, and relebactam. New Delhi metallo-beta-lactamase (NDM), which is not inactivated by the newer generation BLI, was relatively rare.

Now, researchers present data from 29 states with mandated CRE isolate submission.